Collaboration to Supply Antiviral Drug Standards to Assist in COVID-19 Research Announced

摘要

Through a commercial partnership with Alsachim,Cambridge Isotope Labs(CIL)is proud to now offer an assortment of unlabelled and stable isotope-labelled antiviral drug standards and their metabolites to assist in COVID-19 research and therapy development."We are thrilled to join forces with CIL in order to answer US customers'needs and deliver crucial compounds for COVID-19 therapeutic monitoring,"said Dr Jean-Francois Hoeffler,President of Alsachim.CIL,the largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds,is now collaborating with Alsachim to provide antiviral drug standards to researchers and clinicians exclusively in the Americas.These products are available through CIL in convenient packaging sizes and are adept for use as internal standards in therapeutic monitoring and quantitative analysis.